Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Related Keywords

Johno Mascarenhas , ,Dynamic International Prognostic Scoring System ,Adult Leukemia Program ,Tisch Cancer Institute ,Myeloproliferative Disorders Program ,Icahn School Of Medicine At Mount Sinai ,Icahn School ,Mount Sinai ,Blood Cancers ,Myeloid Disorders ,Myeloproliferative Disorders ,Myelofibrosis Symptom Assessment Form ,Adv Hematol ,Selinexor ,Jak Inhibitor Naive Myelofibrosis ,Ruxolitinib ,Mpns ,Xport Mf 044 ,Xport Mf 034 ,Xpo1 Inhibitor ,